Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEALS study of dimethyl fumarate in sporadic amyotrophic lateral sclerosis
ACTRN12618000534280Phase 2Not yet recruiting
- Sponsor
- University of Sydney
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Dimethyl fumarate with Placebo (2 arms). Primary endpoint: ALS progression by ALS Functional Rating Scale-Revised. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
dimethyl fumarate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ACTRN12618000534280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000534280.